In the Matter of
CERTAIN FLOCKED SWABS,
PRODUCTS CONTAINING FLOCKED
SWABS, AND METHODS OF USING
SAME

Investigation No. 337-TA-1279

NOTICE OF A COMMISSION DETERMINATION NOT TO REVIEW AN
INITIAL DETERMINATION TERMINATING INVESTIGATION AS TO CERTAIN
CLAIMS OF THE ASSERTED PATENTS


ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has
determined not to review an initial determination (“ID”) (Order No. 68) of the presiding
Administrative Law Judge (“ALJ”) terminating the investigation as to certain claims of the
asserted patents.

FOR FURTHER INFORMATION CONTACT: Michael Liberman, Esq., Office of the
General Counsel, U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C.
20436, telephone (202) 205-2392. Copies of non-confidential documents filed in connection
with this investigation may be viewed on the Commission’s electronic docket (EDIS) at
https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General
information concerning the Commission may also be obtained by accessing its Internet server at
https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter
can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: On September 2, 2021, the Commission instituted
this investigation under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337,
based on a complaint filed by Copan Italia S.p.A. and Copan Industries, Inc. (“Copan,” or
“Complainants”). 86 FR 49343-44 (Sept. 2, 2021). The complaint alleged a violation of
section 337 in the importation into the United States, the sale for importation, or the sale within
the United States after importation of certain flocked swabs, products containing flocked swabs,
and methods of using same by reason of infringement of claims 1, 6-9, 11-14, 16-19, and 21-22
of U.S. Patent No. 9,011,358 (“the ’358 patent”); claims 1, 4-6, 8, 9, 11-13, 16-20, and 22-24 of
U.S. Patent No. 9,173,779 (“the ’779 patent”); and claims 1, 3, 5, 7-10, 18, and 20 of U.S. Patent
No. 10,327,741 (“the ’741 patent”). The complaint also alleged the existence of a domestic
industry.

The notice of investigation named as respondents Han Chang Medic of Chungnam, Republic of Korea (“HCM”); Wuxi NEST Biotechnology Co., Ltd. of Wuxi, Jiangsu, China; NEST Scientific Inc. and NEST Scientific USA, both of Rahway, New Jersey; Miraclean Technology Co., Ltd. of Shenzhen, Guangdong, China; Vectornate Korea Ltd. of Jangseong, Republic of Korea and Vectornate USA, Inc. of Mahwah, New Jersey (collectively, “Vectornate”); Innovative Product Brands, Inc. of Highland, California (“IPB”); Thomas Scientific, Inc. of Swedesboro, New Jersey (“Thomas Inc.”); Thomas Scientific, LLC (“Thomas LLC”) and Stellar Scientific, LLC (“Stellar”), both of Owings Mills, Maryland; Cardinal Health, Inc. of Dublin, Ohio (“Cardinal”); KSL Biomedical, Inc. and KSL Diagnostics, Inc., both of Williamsville, New York (collectively, “KSL”); Jiangsu Changfeng Medical Industry Co., Ltd. of Yangzhou, Jiangsu, China; No Borders Dental Resources, Inc., dba MediDent Supplies of Queen Creek, Arizona (“MediDent”); BioTeke Corporation (Wuxi) Co., Ltd. of Wuxi, Jiangsu, China; Fosun Pharma USA Inc. (“Fosun”) of Princeton, New Jersey; Hunan Runmei Gene Technology Co., Ltd. of Changsha, Hunan, China (“Runmei”); VWR International, LLC of Radnor, Pennsylvania (“VWR”); and Simp, LLC dba StatLab Medical Products of McKinney, Texas (StatLab). Id. at 49343-44. The Commission’s Office of Unfair Import Investigations (“OUII”) is also named as a party in this investigation. Id. at 49344. Huachenyang (Shenzhen) Technology Co., Ltd. (“HCY”) and HCY USA, LLC were allowed to intervene as respondents in this investigation. Order No. 30 (Dec. 7, 2021), unreviewed by Notice (Jan. 6, 2021).

Subsequently, the investigation was terminated as to the KSL respondents, Thomas Inc., Thomas LLC, Cardinal, VWR, Vectornate, IPB, Stellar, HCY, StatLab, and Fosun. Order No. 20 (Nov. 15, 2021), unreviewed by Comm’n Notice (Dec. 6, 2021); Order Nos. 21-25 (all issued on Nov. 15, 2021), unreviewed by Comm’n Notice (Dec. 6, 2021); Order No. 33, unreviewed by Comm’n Notice (Jan. 10, 2022); Order No. 35 (Jan. 24, 2022), unreviewed by Notice (Feb. 16, 2022); Order No. 46 (May 3, 2022), unreviewed by Notice (May 27, 2022); Order No. 47 (May 4, 2022), unreviewed by Notice (May 27, 2022). Furthermore, respondents Runmei; HCM; and MediDent were found in default. Order No. 27 (Nov. 15, 2021), unreviewed by Comm’n Notice (Dec. 6, 2021); Order No. 31, unreviewed by Comm’n Notice (Jan. 10, 2022).

The Commission also subsequently terminated the investigation as to claim 7 of the ’358 patent, claims 5 and 19 of the ’779 patent, and claim 8 of the ’741 patent. Order No. 32 (Dec. 15, 2021), unreviewed by Comm’n Notice (Jan. 10, 2022). The Commission also terminated the investigation as to claims 9 and 21 of the ’358 patent and claim 11 of the ’779 patent. Order No. 37 (Jan. 28, 2022), unreviewed by Notice (Feb. 16, 2022).

On May 25, 2022, complainants Copan filed a motion to terminate the investigation as to certain claims of the asserted patents (“Mot.”). Respondents Wuxi NEST Biotechnology Co., Ltd.; NEST Scientific Inc.; NEST Scientific USA; Jiangsu Changfeng Medical Industry Co., Ltd.; BioTeke Corporation (Wuxi) Co., Ltd.; Miraclean Technology Co., Ltd.; Huachenyang
Copan seeks termination of the investigation with respect to claim 11 of the ’358 patent and claim 7 of the ’741 patent based on Copan’s withdrawal of its allegations in the complaint with respect to these claims. Mot. at 1. Copan submits that terminating the claims “will simplify the Investigation, streamline the hearing, and conserve judicial and private party resources.” Id. at 3.

On July 11, 2022, the ALJ issued the subject ID (Order No. 68) granting the motion. The ID noted that, in accordance with Commission Rule 210.21(a)(1), 19 CFR 210(a)(1), Copan represents that “there are no agreements, written or oral, express or implied between Complainants and Respondents concerning the subject matter of the Investigation relevant to the adjudication of this motion.” Id at 3-4 (citing Mot. at 4). The ID found no extraordinary circumstances that prevent terminating claim 11 of the ’358 patent and claim 7 of the ’741 patent from this investigation. Id. at 4. The ID also found that the termination of the investigation as to these claims is in the public interest, as public and private resources will be conserved. Id. No party petitioned for review of the ID.

The Commission has determined not to review the subject ID. Accordingly, claim 11 of the ’358 patent and claim 7 of the ’741 patent have been terminated from this investigation. Id. at 5. Claims 1 and 6 of the ’358 patent, claims 1 and 9 of the ’779 patent, and claims 1, 3, 10, and 18 of the ’741 patent remain in the investigation. Id. n. 4.

The Commission vote for this determination took place on August 1, 2022.


By order of the Commission.

Katherine M. Hiner
Acting Secretary to the Commission

Issued: August 1, 2022